Amicus Therapeutics, Inc. (FOLD)
| Market Cap | 5.61B |
| Revenue (ttm) | 245.61M |
| Net Income (ttm) | -295.18M |
| Shares Out | 259.16M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $21.85 |
| Previous Close | $21.84 |
| Change ($) | 0.02 |
| Change (%) | 0.07% |
| Day's Open | 21.90 |
| Day's Range | 21.08 - 22.18 |
| Day's Volume | 5,762,334 |
| 52-Week Range | 6.63 - 24.89 |
CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual...
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (...
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
CRANBURY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel m...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late onset Pompe disease.
On Track for Completing the BLA Submission in 1H2021
The shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) are up 1.3% at $22.69 at last check, after hitting a Nov. 18, all-time-high of $23.19.
CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at th...
Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q3 2020 Results - Earnings Call Transcript
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10.00% and 3.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...
CRANBURY, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suis...
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRANBURY, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, November 5...
Choosing breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy promises superlative returns.
Data Continue to Support Meaningful Effect on Motor and Language Function in Children with Fatal Neurologic Disease Data Continue to Support Meaningful Effect on Motor and Language Function in...
Amicus is making progress on all fronts and the progress is not fully reflected in the company's valuation.
Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in Oc...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentat...
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2020 Results - Earnings Call Transcript
Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.
Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of $250M-$260M
Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.
CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10,...
INDIANAPOLIS, July 22, 2020 /PRNewswire/ -- The National Police Association (NPA) has filed a friend of the court brief asking the U.S. District Court for the District of Oregon to rule agains...
$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Amicus Therapeutics: 2 Potential Blockbusters Make This Stock Worth Considering
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Whether or not one agrees with DOJ’s call to drop its charges against former National Security Advisor Michael Flynn, there should be widespread agreement that Judge Emmet Sullivan has veered ...
Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2020 Results - Earnings Call Transcript
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.00% and 5.80%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the s...
CRANBURY, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel ...
CRANBURY, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel ...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
CRANBURY, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering n...
These five biotech stocks could post life-changing gains for early-bird investors.
Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.
The coronavirus induced sell-off has created a number of attractive buying opportunities.
Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q4 2019 Results - Earnings Call Transcript
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -34.62% and 2.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...
Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About FOLD
Amicus Therapeutics, a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 an... [Read more...]
| Industry Biotechnology | IPO Date May 31, 2007 |
| CEO John Crowley | Employees 584 |
| Stock Exchange NASDAQ | Ticker Symbol FOLD |
Financial Performance
In 2019, FOLD's revenue was $182.24 million, an increase of 99.72% compared to the previous year's $91.25 million. Losses were -$356.39 million, 2.12% more than in 2018.
Analyst Forecasts
According to 10 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is 24.81, which is an increase of 13.55% from the latest price.